Pet Pharm Biotech Co., Ltd. (TPEX:7762)

Taiwan · Delayed Price · Currency is TWD

56.00

-0.50 (-0.88%)

At close: Sep 10, 2026

Pet Pharm Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	218.91	268.65	181.79	168.49	16.76
Short-Term Investments	191.17	250.21	206.14	-	-
Cash & Short-Term Investments	410.09	518.86	387.93	168.49	16.76
Cash Growth	-28.27%	33.75%	130.25%	905.52%	-
Receivables	54.58	59.35	33.78	31.24	20.91
Inventory	12.88	14.64	13.68	10.8	5.81
Prepaid Expenses	4.04	2.06	2.12	2.61	4.79
Other Current Assets	4.58	5.64	4.43	141.28	50.04
Total Current Assets	486.17	600.55	441.93	354.4	98.31
Property, Plant & Equipment	409.4	395.06	290.2	92.45	84.57
Goodwill	8.24	8.24	-	-	-
Other Intangible Assets	81.81	85.09	9.08	4.05	5.08
Long-Term Deferred Tax Assets	2.83	2.83	2.09	-	-
Other Long-Term Assets	356.1	255.27	16.76	36.67	3.93
Total Assets	1,345	1,347	760.06	487.58	191.89

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Accounts Payable	3.05	3.1	7.92	4.81	2.91
Current Portion of Long-Term Debt	1.07	0.42	100	-	-
Current Portion of Leases	11.35	11.19	6.42	6.57	4.58
Current Income Taxes Payable	-	0.02	-	-	-
Current Unearned Revenue	4.62	4.81	4.31	3.94	3.09
Other Current Liabilities	60.48	36.72	21.41	16.99	8.88
Total Current Liabilities	80.57	56.25	140.05	32.31	19.46
Long-Term Debt	23.57	17.34	-	-	-
Long-Term Leases	72.16	77.22	37.46	41.63	37.94
Long-Term Deferred Tax Liabilities	0	0	-	-	-
Other Long-Term Liabilities	0.55	0.55	-	-	-
Total Liabilities	176.86	151.36	177.52	73.94	57.4

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Common Stock	572.33	572.33	405.29	371.9	251.9
Additional Paid-In Capital	575.92	574.88	78.72	150.01	-
Retained Earnings	10.85	26.86	14.51	-108.27	-117.42
Comprehensive Income & Other	8.59	-	84.03	-	-
Total Common Equity	1,168	1,174	582.54	413.64	134.48
Minority Interest	-	21.63	-	-	-
Shareholders' Equity	1,168	1,196	582.54	413.64	134.48
Total Liabilities & Equity	1,345	1,347	760.06	487.58	191.89

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Total Debt	108.15	106.16	143.88	48.2	42.52
Net Cash (Debt)	301.93	412.7	244.05	120.29	-25.77
Net Cash Growth	-24.07%	69.11%	102.89%	-	-
Net Cash Per Share	5.21	7.54	5.90	3.99	-1.02
Filing Date Shares Outstanding	58.09	58.09	41.69	38.25	25.18
Total Common Shares Outstanding	58.09	58.09	41.69	38.25	25.18
Working Capital	405.6	544.3	301.88	322.1	78.85
Book Value Per Share	20.10	20.21	13.97	10.81	5.34
Tangible Book Value	1,078	1,081	573.47	409.59	129.4
Tangible Book Value Per Share	18.55	18.60	13.76	10.71	5.14
Land	172.41	172.41	172.41	-	-
Machinery	170.85	147.9	93.4	80.44	83.92
Construction In Progress	21.7	11.16	14.59	-	-
Leasehold Improvements	73.48	73.48	51.47	39.47	35.83